0QV2 Stock Chart & Stats
kr16.20
kr12.00(19.35%)
At close: 4:00 PM EST
kr16.20
kr12.00(19.35%)
Day’s Range― - ―
52-Week Rangekr15.00 - kr74.00
Previous CloseN/A
Volume0.00
Average Volume (3M)62.00
Market Cap
kr502.88M
Enterprise Valuekr667.26
Total Cash (Recent Filing)kr43.52M
Total Debt (Recent Filing)kr157.09M
Price to Earnings (P/E)―
Beta0.07
Next Earnings
Oct 22, 2026EPS Estimate
-0.2Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.24
Shares Outstanding31,043,884
10 Day Avg. Volume0
30 Day Avg. Volume62
Financial Highlights & Ratios
PEG Ratio1.22
Price to Book (P/B)2.21
Price to Sales (P/S)3.23
P/FCF Ratio-96.76
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.13
Revenue Forecast (FY)kr210.28M
Bulls Say, Bears Say
Bulls Say
Operating Cost StructureA solid EBITDA margin indicates that operating cost control has improved despite reported losses. Sustaining this contribution margin could provide operating leverage if revenue expands through additional coated devices and licensing adoption.
Positive Cash GenerationPositive operating and free cash flow improve financial self-funding and reduce reliance on external capital. Although consistency remains unproven, the recovery from negative 2025 cash flow provides a stronger base for ongoing product and commercialization activities.
Scalable Licensing ModelLicensing BIP to medical device manufacturers can extend market reach without requiring Bactiguard to manufacture every coated product itself. Broader device adoption could create recurring, volume-linked income and improve scalability over time.
Bears Say
Ongoing LossesPersistent net income and EBIT losses show that the improved EBITDA contribution has not yet translated into sustainable profitability. This limits internal capital formation and leaves the business more exposed to execution, financing, and commercialization risks.
Gross Margin CompressionThe sharp reduction in gross margin raises durable concerns about product mix, pricing power, manufacturing economics, or one-off effects. Unless reversed, lower gross profit per unit will constrain earnings conversion and weaken the benefit of revenue growth.
Unstable Revenue And Cash TrendsOnly modest revenue growth, combined with volatile cash conversion, makes the recovery difficult to rely on for planning. The company needs broader adoption and more consistent partner or product volumes to establish a durable growth and funding profile.
Bactiguard Holding AB News
0QV2 FAQ
What was Bactiguard Holding AB’s price range in the past 12 months?
Bactiguard Holding AB lowest share price was kr15.00 and its highest was kr74.00 in the past 12 months.
What is Bactiguard Holding AB’s market cap?
Bactiguard Holding AB’s market cap is kr502.88M.
When is Bactiguard Holding AB’s upcoming earnings report date?
Bactiguard Holding AB’s upcoming earnings report date is Oct 22, 2026 which is in 55 days.
How were Bactiguard Holding AB’s earnings last quarter?
Bactiguard Holding AB released its earnings results on Jul 14, 2026. The company reported -kr0.2 earnings per share for the quarter, beating the consensus estimate of -kr0.3 by kr0.1.
Is Bactiguard Holding AB overvalued?
According to Wall Street analysts Bactiguard Holding AB’s price is currently Overvalued.
Does Bactiguard Holding AB pay dividends?
Bactiguard Holding AB pays a Notavailable dividend of kr0.285 which represents an annual dividend yield of N/A. See more information on Bactiguard Holding AB dividends here
What is Bactiguard Holding AB’s EPS estimate?
Bactiguard Holding AB’s EPS estimate is -0.2.
How many shares outstanding does Bactiguard Holding AB have?
Bactiguard Holding AB has 31,043,884 shares outstanding.
What happened to Bactiguard Holding AB’s price movement after its last earnings report?
Bactiguard Holding AB reported an EPS of -kr0.2 in its last earnings report, beating expectations of -kr0.3. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Bactiguard Holding AB?
Currently, no hedge funds are holding shares in GB:0QV2
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Bactiguard Holding AB
Bactiguard Holding AB (publ), a Swedish-based global medical technology company, specializes in developing and supplying innovative solutions designed to prevent infections. Its primary objective is to mitigate healthcare-associated infections (HAIs) and reduce the global dependency on antibiotics. The core of Bactiguard's product line, known as Bactiguard Infection Protection (BIP), encompasses a range of coated medical devices. This includes various urinary catheters, such as the BIP Foley Catheter and the temperature-sensing BIP Foley TempSensor, all engineered to inhibit microbial adhesion and prevent urinary tract infections. Similarly, the BIP Central Venous Catheter and BIP Endotracheal Tube (with the BIP Endotracheal Tube Evac variant offering subglottic secretion drainage) work to reduce the risk of bloodstream and respiratory tract infections by minimizing biofilm formation. Beyond its BIP portfolio, the company offers a diverse array of other products, including Hydrocyn aqua advanced wound care for cleaning and debriding acute, chronic, and infected wounds, as well as general Bactiguard Wound Care items. It also provides a comprehensive selection of surgical sutures (natural absorbable, synthetic absorbable, non-absorbable, and specialty types), VigiMesh for hernia repair, and Hydrocyn aqua advanced disinfectant for sanitizing skin and surfaces. Additionally, Bactiguard supplies specialized orthopedic trauma implants featuring infection prevention technology under the ZNN Bactiguard brand, and the Aniocyn line of wound and skin care products for various pets. Bactiguard Holding AB (publ) was established in 2005 and maintains its headquarters in Tullinge, Sweden.